Australia: A turning of the tide: interlocutory injunctions in Australian pharma patent cases

Last Updated: 25 September 2019
Article by David Fixler

Over the course of at least a decade, patentees in pharmaceutical patent cases have had a very strong track record of obtaining interlocutory injunctions to prevent the launch of generic products in Australia. The Federal Court's recent experience in assessing claims for compensation, when restrained generic pharmaceutical companies have ultimately succeeded (because the patent was revoked or not infringed), has resulted in a fundamental shift in its approach.

Patentees can no longer safely assume that the Federal Court (Court) will readily come to their aid to prevent a generic or biosimilar launch on the basis that the launch will result in a significant price reduction and irreparable harm to the patentee. Rather, patentees will need to work harder to persuade the Court of the strength of their infringement case and the complexities involved in assessing damages having regard to the particular market in question.

Those seeking to launch generic and biosimilar products with strong revocation or non-infringement positions may well be able to defend an interlocutory injunction, including by highlighting the complexities that would be involved in a compensation claim if it ultimately succeeds. They are likely to find themselves 'preaching to the converted'.

A strong track record in favour of patentees

Prior to 2018, the Court had demonstrated a strong tendency to grant interlocutory injunctions to restrain the launch of a generic or biosimilar in pharmaceutical patent cases. In assessing whether to grant an interlocutory injunction, the Court considers:

  • the strength of the infringement case (including any cross-claim for revocation of the patent); and
  • the balance of convenience including whether damages will be an adequate remedy.

Importantly, the two limbs of the test are interrelated, so that the weaker the infringement case, the more the balance will need to weigh in the patentee's favour and vice versa.

An unavoidable condition of obtaining an interlocutory injunction is that the patentee must give the 'usual undertaking as to damages' to compensate parties adversely affected by the injunction if, as it transpires, that injunction ought not to have been granted.

In Australia, many medicines are subsidised by the Federal (Commonwealth) Government under the Pharmaceutical Benefits Scheme (PBS). The launch of a first generic or biosimilar product will cause an automatic price drop (now 25%) in the price at which the reference product (and any generic) will be subsidised. A patentee will also generally be forced to implement 'voluntary' price reductions to effectively compete with a generic entrant.

Interlocutory injunctions were granted to restrain the launch of a range of generic and biosimilar products.1 Patentees argued, and the Court accepted, that the balance of convenience weighed in their favour because generic launch would trigger a price drop with the consequence that they would suffer irreparable harm as their loss would be unquantifiable. For example, in MSD v Apotex Justice Jagot found:

"... it is likely that Apotex's entry into the market (being the market of intra-nasal corticosteroid sprays) will cause significant structural change in terms of pricing and market shares which will not be readily changed should Merck obtain final relief and which exposes Merck to unquantifiable loss not only in terms of pricing changes but also loss of staff, the need to re-train staff if Apotex is ultimately restrained, as well as loss of goodwill."2

The earliest sign that the tide was turning may have been Justice Burley's acknowledgment in Roche v Sandoz that Sandoz "will face significant complexities in establishing its claim on the undertaking as to damages". His Honour was influenced by the fact that at that time there were three proceedings before the Court involving complex compensation claims by parties who were ultimately found to have been wrongly prevented from launching generic products – these included claims relating to venlafaxine, clopidogrel and rosuvastatin. His Honour, nevertheless, granted the interlocutory injunction.

The turning point

The landscape changed as a consequence of two cases heard by Justice Jagot in which decisions were handed down in late 2018.

The first case was a claim made by a number of generic pharmaceutical companies who were wrongly restrained from launching venlafaxine products in 2009 in circumstances were the patent was ultimately found to be invalid. In the judgment in Sigma v Wyeth, her Honour identified:

"It is difficult to imagine that when Sundberg J and then I granted the interlocutory injunctions in 2009 we anticipated that if those injunctions turned out to be wrongly granted, the resulting exercise would bear any resemblance to this one. Hindsight makes one thing certain. Knowing what has occurred, it could never have been concluded, for example, that insofar as relevant to the balance of convenience it would be easier for the generics to prove their loss if the interlocutory injunctions were wrongly granted than for Wyeth to prove its loss if the interlocutory injunctions were withheld and the method patent was valid."3

The second case was a damages claim by Lundbeck for losses suffered by reason of the sale of generic companies selling products which infringed its patent for its blockbuster anti-depressant LEXAPRO. In Lundbeck v Sandoz, Justice Jagot found:

"...instead of requiring econometric modelling to ascertain prices and market shares Lundbeck could rely on the prices and market shares actually involved in generic entry into the market.
It may be apparent from this that it was far easier for Lundbeck to prove the value of its loss on the basis of the generics having entered the market than it was for the generics in Sigma to prove the value of their loss on the basis that they were wrongfully held out of the market."4

The Court's new approach

It did not take long for Justice Jagot's position to find favour with other members of the Court.

In December 2018, Justice Burley refused an application by Sanofi-Aventis seeking an interlocutory injunction to restrain Alphapharm from launching its Semglee pen for delivering insulin in Sanofi v Alphapharm. Justice Burley found that "there was a real and substantial prospect" that the patent lacked novelty and that the balance of convenience favoured refusal of the injunction. While Sanofi argued that its products would be subject to a 25% price drop, Burley J considered that:

"...having regard to the relative complexities between the two, I consider that the calculation of loss likely to be suffered by Alphapharm having regard to a hypothetical launch is likely to be more difficult as a vehicle for recompense than the calculation of loss for Sanofi, even taking into account the consequential effects of price drops that arise because Semglee is listed on the PBS Schedule and the uncertainties associated with future market conditions."5

In his reasons for refusing the injunction (at [166]), Burley J quoted the paragraph above from Justice Jagot in Sigma v Wyeth. Sanofi's appeal against Burley J's decision was unanimously dismissed by the Full Court.6

The last chapter in this story took place in April this year when Mylan sought to restrain Sun Pharma and Cipla from launching generic versions of its fenofibrate product LIPIDIL. Mylan's applications for injunctions restraining Sun Pharma and Cipla were heard together by Justice Yates who refused to the applications. Mylan faced added difficulty because its patents had been found invalid by the Court at first instance and it sought interlocutory injunctions in aid of its appeal. However, the Court has previously granted an injunction in such circumstances.7

While Justice Yates acknowledged that Mylan's grounds of appeal were "arguable", his Honour held that the balance of convenience weighed in favour of Sun Pharma and Cipla (consistent with the views expressed by Justice Jagot in Sigma v Wyeth and Lundbeck v Sandoz, and by Justice Burley in Sanofi v Alphapharm):

"The most compelling reason for the conclusion to which I have come is the difficulty, complexity and uncertainty involved in assessing compensation under an undertaking as to damages given in patent infringement proceedings involving the supply of pharmaceutical products in the Australian market. I accept that the recent experience of the Court has demonstrated that, whatever general views might have been held in the past about the difficulty of that task compared with the task of assessing damages for infringement, the calculation of compensation under an undertaking as to damages can impose burdens and raise uncertainties that are far greater than the burdens and uncertainties involved in assessing damages for infringement. The differential nature of these burdens and uncertainties is captured by Jagot J's observations in Sigma and Lundbeck, which I have quoted above...Her Honour's observations in Sigma reflect my own view as to the likely difficulty, complexity and uncertainty that would be involved in assessing compensation under an undertaking as to damages in the present case."8

Key takeaways

Pharmaceutical companies seeking to launch or prevent the launch of generic or biosimilar products in Australia cannot afford to ignore the fundamental shift in the Court's position when it comes to assessing the balance of convenience.

Innovators will, of course, continue to pursue interlocutory injunctions. However, they will need to carefully consider how to persuade the Court of:

  • the strength of the infringement case; and
  • difficulties in quantifying their loss because of, for example, changes to the market affected by generic launch (resulting in uncertainty that every generic sale would have been made by the patentee) or difficulties assessing the contribution of multiple generic companies to price reductions.

Despite the Court's shift, those seeking to launch generic or biosimilar products are still best placed to avoid an infringement claim (and an interlocutory injunction) by seeking to 'clear the way' early. Importantly, this avoids the risk of liability for the price reduction. If this is too late and the generic is confident of defeating any infringement claim (including by reason of strong invalidity position), generics should take advantage of the Court's new approach by resisting applications for interlocutory injunctions by demonstrating the complexity of quantifying its loss if is wrongly prevented from launching and ultimately succeeds.

Disclosure: Corrs acted for Lundbeck in H. Lundbeck A/S v Sandoz Pty Ltd [2018] FCA 1797, two of the claimants in Sigma Pharmaceuticals (Australia) Pty Ltd v Wyeth [2018] FCA 1556 and Cipla in Mylan Health Pty Ltd v Cipla Australia Pty Ltd [2019] FCA 506.


1 These included: clopidogrel (GenRx Pty Ltd v Sanofi-Aventis [2007] FCA 1485); venlafaxine (Sigma Pharmaceuticals (Australia) Pty Ltd (ACN 004 118 594) v Wyeth [2009] FCA 595 (Sigma v Wyeth)); rosuvastatin (Apotex Pty Ltd v AstraZeneca AB [2011] FCA 1520), zoledronic acid (Novartis AG v Hospira Pty Limited [2012] FCA 1055); corticosteroid mometasone furoate (Merck Sharp & Dohme Corp v Apotex Pty Ltd [2012] FCA 928 (MSD v Apotex)); raloxifene (Eli Lilly and Company v Generic Health Pty Ltd [2013] FCA 1254); aripiprazole (Generic Health Pty Ltd v Otsuka Pharmaceutical Co Ltd [2013] FCAFC 17); pregabalin (Warner-Lambert Company LLC v Apotex Pty Ltd [2014] FCAFC 59; azelastine hydrochloride and fluticasone propionate (DYMISTA) (Apotex Pty Ltd v Cipla Limited [2017] FCA 1627); dexmedetomidine (InterPharma Pty Ltd v Hospira, Inc (No 3) [2017] FCA 1536; and rituximab (MABTHERA) (F. Hoffman-La Roche AG v Sandoz Pty Ltd [2018] FCA 874 (Roche v Sandoz)).

2 See Merck Sharp & Dohme Corp v Apotex Pty Ltd [2012] FCA 928 at [28]

3 See Sigma Pharmaceuticals (Australia) Pty Ltd (ACN 004 118 594) v Wyeth [2009] FCA 595 at [1336]

4 See H. Lundbeck A/S v Sandoz Pty Ltd [2018] FCA 1797 at [382]–[383]

5 See Sanofi-Aventis Deutschland GmbH v Alphapharm Pty Ltd (No 3) [2018] FCA 2060 at [188]

6 Comprised by Justices Jagot, Yates and Moshinsky, see Sanofi-Aventis Deutchsland GmbH v Alphapharm Pty Ltd [2019] FCAFC 28

7 Otsuka Pharmaceuticals Co., Ltd v Generic Health Pty Ltd [2015] FCA 848)

8 See Mylan Health Pty Ltd v Sun Pharma ANZ Pty Ltd (No 2) [2019] FCA 505 at [137]

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Chambers Asia Pacific Awards 2016 Winner – Australia
Client Service Award
Employer of Choice for Gender Equality (WGEA)

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions